TABLE 1

Demographic details and clinical outcomes relative to physical activity performance

	≥30MVPA	<30MVPA	MVPA-Bouts	MVPA-No Bouts
Baseline
Subjects	33	28	21	40
Male:female	22:11	10:18	14:7	22:18
Age years	29.9±6	32.6±10	29.5±6	32.0±9
BMI kg·m⁻²	21.8±1.8	22.6±3.6	21.9±2.2	22.3±3.1
Pancreatic insufficiency	31	27	20	37
CF-related diabetes	7	7	5	9
FEV₁ L	2.8±0.9	2.3±1.0	2.9±1.0	2.3±0.9
FEV₁ % predicted	69±18	65±23	71±20	64±20
1-year follow-up
FEV₁ L	2.8±0.9	2.2±1.1	2.9±0.9	2.3±1.0
FEV₁ % predicted	69±19	64±26	72±21	63±23
Annual change in FEV₁ L	−0.01±0.2	−0.03±0.2	0.02±0.2	−0.04±0.2
Hospitalisation frequency
0	17	9	13	13
1–2	11	13	6	17
>2	5	6	2	10
Total hospitalisations, median (IQR)	0 (0–2)	1.5 (0–2)	0 (0–2)	1 (0–2)
Total hospital days, median (IQR)	0 (0–19)	27 (0–49)	0 (0–25)	12 (0–44)
3-year follow-up
Complete cases	29	24	18	34
Male: Female	21:8	8:16	13:5	15:19
FEV₁ L	2.7±1.0	2.2±1.1	2.9±1.0	2.2±1.0
FEV₁ % predicted	66±20	63±28	71±21	61±25
Annual change FEV₁ L	−0.03±0.12	−0.05±0.09	0.01±0.1	−0.07±0.1
Hospitalisation frequency
0	5	4	4	7
1–2	10	5	7	7
>2	14	15	7	20
Total hospitalisations, median (IQR)	2 (1–7)	4 (1–7)	2 (0.8–6)	4 (1–7)
Total hospital days, median (IQR)	19 (4–100)	51 (10–115)	17 (6–92)	44 (9–119)

Data are presented as n or mean±sd, unless otherwise stated. MVPA: moderate-vigorous physical activity; ≥30MVPA: spent at least 30 min in MVPA daily; <30MVPA: did not achieve at least 30 min MVPA daily; MVPA-Bouts: achieved 30 min MVPA in bouts of ≥10 min duration; MVPA-No Bouts: did not achieve 30 min MVPA in bouts of ≥10 min duration; BMI: body mass index; CF: cystic fibrosis; FEV₁: forced expiratory volume in 1 s; IQR: interquartile range.